Xenon Pharmaceuticals Inc.
Close on Oct 19, 2026
- Market cap
- $3.49B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 2, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | After market close | – | $-1.11 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | After market close | – | $-1.17 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 3, 2025 | After market close | – | $-1.15 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 11, 2025 | After market close | – | $-1.07 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 12, 2025 | After market close | $7.50M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | After market close | – | $-0.81 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 29, 2024 | After market close | – | – | – |
Press releases
Announcements Xenon Pharmaceuticals filed with the SEC
Xenon Reports Q2 2026 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Xenon Reports Q1 2026 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner
Regulation FD disclosure · EX-99.1 to Form 8-K
On Today’s Call Ian Mortimer Chris Kenney, MD Darren Cline Tucker
Regulation FD disclosure · EX-99.2 to Form 8-K
Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Xenon Reports Third Quarter 2025 Financial Results & Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer
Executive or director change · Other events · EX-99.1 to Form 8-K/A
Xenon Reports Second Quarter 2025 Financial Results & Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Xenon Reports First Quarter 2025 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Xenon Reports Q3 2024 Financial Results and Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Xenon Reports Q2 2024 Financial Results and Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences
Other events · EX-99.1 to Form 8-K
Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Xenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
Xenon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99 to Form 8-K
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99 to Form 8-K
Xenon Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Xenon Pharmaceuticals Strengthens Leadership Team with Appointment of Andrea DiFabio
Other events · EX-99.1 to Form 8-K
Xenon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Xenon Pharmaceuticals Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA
Other events · EX-99.1 to Form 8-K
Xenon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
American Stock Transfer & Trust Company, LLC
Results of operations · Other events · EX-99.1 to Form 8-K
Xenon Pharmaceuticals Reports 2021 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences
Unregistered share sale · Other events · EX-99.1 to Form 8-K
Xenon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K